Brief Title: NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

• Pancreatic Cancer
• Breast Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer
• Cervical Cancer
• Endocervical Cancer
• Squamous Cell Carcinoma of Head and Neck
• Bladder Urothelial Cancer
• Colorectal Carcinoma
• Esophageal Cancer
• Ovarian Cancer
• Renal Cell Carcinoma
• Prostate Cancer
• Melanoma
• Mesothelioma
• Cholangiocarcinoma

ELIGIBILITY

Inclusion Criteria:
* Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.

- * Adequate bone marrow, kidney and liver function

- * Performance status of 0 or 1.

- * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
Exclusion Criteria:
* Prior treatment targeting ILT3.

- * Prior treatment targeting LAIR1.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: N/A

Role: N/A

Affiliation: N/A

Overall Contact

Name: NGM Medical Director

Phone: (650) 243-5555

Email: NGM831@ngmbio.com

LOCATION